What do systematic reviews say?

Intervention not reported

The review found no eligible studies for this question.

• Compression therapy for treating post‐thrombotic syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Compression therapy for treating post‐thrombotic syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Compression therapy for treating post‐thrombotic syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in severity post‐thrombotic syndromeb ( (low certainty).

• Compression therapy for treating post‐thrombotic syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 47 participants
  Low

Intervention not reported

• Compression therapy for treating post‐thrombotic syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 32 participants
  Moderate

Intervention not reported

• Compression therapy for treating post‐thrombotic syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 32 participants
  Moderate

Intervention not reported

The review found no eligible studies for this question.

• Compression therapy for treating post‐thrombotic syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Patient‐centred outcomes for oral vs IV iron

Patient‐centred outcomes for oral showed no clear difference in death (all causes) compared with IV iron (low certainty).

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  RR 1.12 [0.64, 1.94]
  11 studies · 1952 participants
  Low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  33 studies · 3389 participants
  Low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  27 studies · 3089 participants
  Low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 152 participants
  Very low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 522 participants
  Low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1052 participants
  Low

Patient‐centred outcomes for oral vs IV iron

It is very uncertain whether patient‐centred outcomes for oral changes cardiovascular death compared with IV iron (very low certainty).

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  RR 1.71 [0.41, 7.18]
  3 studies · 206 participants
  Very low

Patient‐centred outcomes for oral vs IV iron

Patient‐centred outcomes for oral may leads to higher type of adverse event: allergic reactions/hypotension compared with IV iron (low certainty).

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  RR 3.56 [1.88, 6.74]
  15 studies · 2607 participants
  Low

Patient‐centred outcomes for oral vs IV iron

Patient‐centred outcomes for oral may leads to lower type of adverse event: all gastrointestinal adverse effects compared with IV iron (low certainty).

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  RR 0.47 [0.33, 0.66]
  14 studies · 1986 participants
  Low

Patient‐centred outcomes for oral vs IV iron

Patient‐centred outcomes for oral showed no clear difference in type of adverse event: infection compared with IV iron (low certainty).

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  RR 1.32 [0.9, 1.95]
  4 studies · 954 participants
  Low

Patient‐centred outcomes for oral vs IV iron

Patient‐centred outcomes for oral showed no clear difference in numbers of non‐dialysis patients needing to commence dialysis compared with IV iron (low certainty).

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  RR 0.81 [0.41, 1.61]
  4 studies · 743 participants
  Low

Patient‐centred outcomes for oral vs IV iron

Patient‐centred outcomes for oral showed no clear difference in number requiring transfusion compared with IV iron (low certainty).

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  RR 0.86 [0.55, 1.34]
  5 studies · 774 participants
  Low

Intervention not reported

The intervention may leads to higher number achieving target Hb or increase ≥1 g/dL (low certainty).

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  RR 1.71 [1.43, 2.04]
  13 studies · 2206 participants
  Low